SMOC1 and prostate adenocarcinoma: Compared with levels in normal tissue, the expression of SMOC1 was aberrantly in many cancers; it was reduced in bladder urothelial carcinoma, BRCA, cholangiocarcinoma, kidney renal clear cell carcinoma, kidney renal papillary cell carcinoma, liver hepatocellular carcinoma, prostate adenocarcinoma, thyroid carcinoma, and uterine corpus endometrial carcinoma but increased in kidney chromophobe, LUAD, and LGG.